References
Boehringer Ingelheim. Boehringer Ingelheim Shows Continued Growth. Media Release: 1 Aug 2005. Available from URL: http://www.boehringer-ingelheim.com
Boehringer Ingelheim Pharmaceuticals Inc. US FDA Approves New Anti-HIV Drug Aptivus for Use in Combination Therapy. Media Release: 23 Jun 2005. Available from URL: http:// us.boehringer-ingelheim.com
Boehringer Ingelheim Pharmaceuticals Inc. FDA Antiviral Drugs Advisory Committee Recommends Accelerated Approval for Investigational Anti-HIV Drug Tipranavir. Media Release: 19 May 2005. Available from URL: http://us.boehr-inger-ingelheim.com
Boehringer Ingelheim. Boehringer Ingelheim Submits Marketing Authorisation Application to European Union and to the FDA for Investigational Anti-HIV Agent Tipranavir. Media Release: 25 Oct 2004. Available from URL: http:// www.boehringer-ingelheim.com
Boehringer Ingelheim. Positive Opinion in Europe for Tipranavir. Media Release: 28 Jul 2005. Available from URL: http://www.boehringer-ingelheim.com
Boehringer Ingelheim. Boehringer Ingelheim launches global phase III clinical trials for new anti-HIV agent Tipranavir. Media Release: 6 Feb 2003. Available from URL: http:// www.boehringer-ingelheim.com
Boehringer Ingelheim. Boehringer Ingelheim Announces 24-Week Interim Results from Tipranavir RESIST-1 Phase 3 Study. Media Release: 1 Nov 2004. Available from URL: http://www.us.boehringer-ingelheim.com
Boehringer Ingelheim GmbH. Boehringer Ingelheim Expands International Compassionate Use Program for Anti-HIV Drug Tipranavir to Include Several Thousand Patients Worldwide. Media Release: 22 Jun 2004. Available from URL: http:// www.boehringer-ingelheim.com
Boehringer Ingelheim Pharmaceuticals Inc. Boehringer Ingelheim Announces US Expanded Access Program for Anti-HIV Drug Tipranavir. Media Release: 30 Nov 2004. Available from URL: http://us.boehringer-ingelheim.com
Boehringer Ingelheim. Boehringer Ingelheim Announces 24-Week Results From Second Phase III Pivotal Study of Tipranavir. Media Release: 18 Nov 2004. Available from URL: http://www.boehringer-ingelheim.com
Borin MT, Schneck DW, Wang Y. Multiple-dose, safety, tolerance and pharmacokinetics of the protease inhibitor PNU-140690 in healthy volunteers. 5th Conference on Retroviruses and Opportunistic Infections: abstr. 648, 1 Feb 1998
Borin MT, Tutton CM, Wang Y. The safety, tolerance, pharmacokinetics, and efficacy of PNU-140690, a new non-peptidic HIV protease inhibitor, in a phase I/II study. 12th World AIDS Conference: 777, 28 Jun 1998
Boehringer Ingelheim. Tipranavir, first non-peptidic protease inhibitor, shown to suppress HIV in patients where multiple protease inhibitor-based regimens have failed–Boehringer Ingelheim presents phase II data. Media Release [3 pages]: 9 Jul 2001. Available from URL: http://www.boehringer-in-gelheim.com
Boehringer Ingelheim Pharmaceuticals Inc. 80-Week Phase II Data of Tipranavir-Based Antiretroviral Therapy Presented at 9th European AIDS Conference. Media Release: 30 Oct 2003. Available from URL: http://us.boehringer-ingelheim.com
Farthing C, Haas D, Jayaweera J, et al. Safety and efficacy of tipranavir, a novel non-peptidic protease inhibitor, plus ritonavir, in PI-failure patients. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy: Late Breaker Abstracts: 13, 16 Dec 2001
Arasteh K, Gathe J, Kohlbrenner VM, et al. Tipranavir/ritonavir demonstrates potent efficacy in multiple protease inhibitor experienced patients: BI 1182.52. 10th Conference on Retroviruses and Opportunistic Infections: abstr. 179, 10 Feb 2003. Available from URL: http://www.retroconference.org
Baldwin JR, Borin MT, Wang Y. Effects of food and antacid on bioavailability of the protease inhibitor PNU-140690 in healthy volunteers. 5th Conference on Retroviruses and Opportunistic Infections: abstr. 649, 1 Feb 1998
Azie NE, Baldwin JR, Borin MT, et al. Pharmacokinetic interaction between the HIV protease inhibitors tipranavir and ritonavir. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy: 24, 26 Sep 1999
Baldwin J, Borin M, Lamson M. et al. Pharmacokinetics of tipranavir and nevirapine. Canadian Journal of Infectious Diseases 12 (Suppl. B): 40, May–Jun 2001
Chong K-T, Poppe SM, Slade DE. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrobial Agents and Chemotherapy 41: 1058–1063, May 1997
Chong K-T, Pagano PJ. In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates. Antimicrobial Agents and Chemotherapy 41: 2367–2373, Nov 1997
Citterio P, Kurtagic S, La Seta Catamancio S, et al. Susceptibility to PNU-140690 (tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrobial Agents and Chemotherapy 44: 1328–1332, May 2000
Bloor S, DeCian W, Hertogs K, et al. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 14: 1943–1948, 8 Sep 2000
Hathaway B, Kazanjian P, Markowitz M. et al. Resistance to tipranavir is uncommon in a randomized trial of tipranavir/ ritonavir in multiple PI-failure patients (BI 1182.2). 9th Conference on Retroviruses and Opportunistic Infections: abstr. 562-T (plus poster), 24 Feb 2002
Daenzer C, Nickens D, TIPRANAVIR Team, et al. The safety, efficacy and viral dynamics analysis of tipranavir, a new-generation protease inhibitor, in a phase II study in antire-troviral-naive HIV-1-infected patients. 7th Conference on Retroviruses and Opportunistic Infections: abstr. 673, 30 Jan 2000
Boehringer Ingelheim. Phase II Study Finds Tipranavir Suppresses HIV/AIDS Virus Resistant To Available Protease Inhibitors. Media Release: 5 Jul 2002. Available from URL: http://www.boehringer-ingelheim.com
Boehringer Ingelheim Pharmaceuticals Inc. Boehringer Ingelheim presents late-breaking data on tipranavir, first non-peptidic protease inhibitor (NPPI). Media Release [2 pages]: 18 Dec 2001. Available from URL: http://www.boehringer-ingelheim.com
Cooper D, Hall D, Jayaweera D, et al. Baseline phenotypic suceptibility to tipranavir/ritonavir is retained in isolates from patients with multiple protease inhibitor experience (BI 1182.52). 10th Conference on Retroviruses and Opportunistic Infections: abstr. 596 (plus poster), 10 Feb 2003. Available from URL: http://www.retroconference.org
Cahn P, Cooper D, Hicks C, et al. 24-Week RESIST Study analyses: the efficacy of tipranavir/ritonavir is superior to lopinavir/ritonavir, and the TPV/r treatment response is enhanced by inclusion of genotypically active antiretrovirals in the optimized background regimen. 12th Conference on Retroviruses and Opportunistic Infections: abstr. 560, 22 Feb 2005. Available from URL: http://www.retroconference.org
Boehringer Ingelheim GmbH. Efficacy of Investigational Anti-HIV Agent Tipranavir Demonstrated by New Data. Media Release: 28 Feb 2005. Available from URL: http://www.boeh-ringer-ingelheim.com
Hicks C. RESIST-1: a phase 3, randomized, controlled, open-label, multicenter trial comparing tipranavir/ritonavir to an optimized comparator protease inhibitor/ritonavir regimen in antiretroviral experienced patients: 24-week data. 44th Inter-science Conference on Antimicrobial Agents and Chemotherapy: Late Breakers: 15, 30 Oct 2004
Rights and permissions
About this article
Cite this article
Tipranavir. Drugs R D 7, 55–62 (2006). https://doi.org/10.2165/00126839-200607010-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-200607010-00005